{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T06:26:42Z","timestamp":1794551202471,"version":"4.9.1"},"reference-count":87,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Brazil","award":["445040\/2023-8"],"award-info":[{"award-number":["445040\/2023-8"]}]},{"DOI":"10.13039\/100008994","name":"Universidade de Bras\u00edlia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008994","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Decanato de Pesquisa e Inova\u00e7\u00e3o e Biblioteca Central","award":["edigal DPI-BCE no. 001\/2026"],"award-info":[{"award-number":["edigal DPI-BCE no. 001\/2026"]}]},{"DOI":"10.13039\/501100005668","name":"Funda\u00e7\u00e3o de Apoio \u00e0 Pesquisa do Distrito Federal","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005668","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Recent therapeutic advances have transformed the management of atopic dermatitis (AD). Medication withdrawal, dose reduction and dosing interval extension are sometimes necessary when managing AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare the effectiveness of withdrawal, dose reduction and dosing interval extension with that of continuation of systemic therapy in sustaining remission in patients with AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive search of PubMed, Embase, Web of Science and Scopus was conducted. Study selection was performed independently by two reviewers; discrepancies were resolved by a third reviewer. The risk of bias was evaluated using the Cochrane risk-of-bias tool for randomized trials (RoB 2) and the Risk of Bias in Nonrandomized Studies of Interventions (ROBINS-I) tool. The certainty of the evidence was determined in accordance with the GRADE framework. The primary outcome was defined as sustained clinical improvement, measured by a 75% reduction in the Eczema Area and Severity Index (EASI 75), which was assessed 16\u201352 weeks after treatment withdrawal, dose reduction or dosing interval extension. Risk ratios (RRs) were compared using a network meta-analysis (NMA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After the initial search yielded 21 169 references, 89 reports representing 55 studies were included. Raw data analysis indicated that most active treatments showed comparable RRs for EASI 75 maintenance, whereas the discontinuation of oral therapies led to early relapses in AD activity. On the basis of 9 studies encompassing 26 pairwise comparisons and 2585 observations across 13 regimens, our NMA revealed that lebrikizumab withdrawal and dosing interval extension conferred a lower risk of EASI 75 response loss than withdrawal, dose reduction or dosing interval extension with other active therapies. A subgroup analysis also revealed that the maintenance of EASI 75 responses after placebo withdrawal or dosing interval extension was greatest for induction dosing with lebrikizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While the withdrawal of systemic therapy is recommended in certain circumstances, such as during vaccination and pregnancy, the evidence reveals an early risk of relapse following the withdrawal of oral treatments. In contrast, biologic therapies resulted in sustained remission rates, even after prolonged withdrawal or dosing interval extension periods.<\/jats:p>\n                    <jats:p>An author video to accompany this article is available online.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljag436","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:46:49Z","timestamp":1790855209000},"source":"Crossref","is-referenced-by-count":0,"title":["Assessment of sustained response to systemic treatment for atopic dermatitis in patients who achieved disease remission: a systematic review and network meta-analysis comparing withdrawal, dose reduction and dosing interval extension versus continuation therapy"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5638-3974","authenticated-orcid":false,"given":"Juliana","family":"Nakano","sequence":"first","affiliation":[{"name":"Postgraduate Programme in Medical Sciences, Faculty of Medicine, University of Bras\u00edlia , Bras\u00edlia ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7402-6346","authenticated-orcid":false,"given":"Let\u00edcia Fernandes","family":"Barroso","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Catholic University of Bras\u00edlia , Bras\u00edlia ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5837-4123","authenticated-orcid":false,"given":"Kleyton de Carvalho","family":"Mesquita","sequence":"additional","affiliation":[{"name":"Postgraduate Programme in Medical Sciences, Faculty of Medicine, University of Bras\u00edlia , Bras\u00edlia ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3069-6884","authenticated-orcid":false,"given":"Ciro Martins","family":"Gomes","sequence":"additional","affiliation":[{"name":"Postgraduate Programme in Medical Sciences, Faculty of Medicine, University of Bras\u00edlia , Bras\u00edlia ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3686-7805","authenticated-orcid":false,"given":"Jonathan I","family":"Silverberg","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The George Washington University School of Medicine and Health Sciences , Washington, DC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"key":"2026111300411206900_ljag436-B1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/bjd\/ljad339","article-title":"Global epidemiology of atopic dermatitis: a comprehensive systematic analysis and modelling study","volume":"190","author":"Tian","year":"2023","journal-title":"Br J Dermatol"},{"key":"2026111300411206900_ljag436-B2","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jaad.2021.12.012","article-title":"From the Cochrane Library: systemic treatments for eczema, a network meta-analysis","volume":"87","author":"Guo","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2026111300411206900_ljag436-B3","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/jdv.19699","article-title":"Early intervention and disease modification in atopic dermatitis \u2013 the current state of the field and barriers to progress","volume":"38","author":"Jacobson","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl. 2","key":"2026111300411206900_ljag436-B4","first-page":"667","article-title":"Maintenance of efficacy and safety with nemolizumab at week 48: results from two global phase 3 pivotal studies (ARCADIA-1 and ARCADIA-2) in patients with moderate-to-severe atopic dermatitis","volume":"191","author":"Silverberg","year":"2024","journal-title":"Br J Dermatol"},{"key":"2026111300411206900_ljag436-B5","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1097\/DER.0000000000000814","article-title":"Patients withdrawing dupilumab monotherapy for COVID-19-related reasons showed similar disease course compared with patients continuing dupilumab therapy","volume":"33","author":"Chiricozzi","year":"2022","journal-title":"Dermatitis"},{"key":"2026111300411206900_ljag436-B6","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/bjd\/ljad022","article-title":"Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials","volume":"188","author":"Blauvelt","year":"2023","journal-title":"Br J Dermatol"},{"key":"2026111300411206900_ljag436-B7","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1111\/jdv.20877","article-title":"Improvement and maintenance of clinical outcome assessments in atopic dermatitis with amlitelimab","volume":"39","author":"Blauvelt","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026111300411206900_ljag436-B8","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s40257-023-00806-3","article-title":"Tralokinumab efficacy over 1\u2005year in adults with moderate-to-severe atopic dermatitis: pooled data from two phase III trials","volume":"24","author":"Simpson","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"2026111300411206900_ljag436-B9","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaad.2021.05.075","article-title":"Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial","volume":"86","author":"Blauvelt","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2026111300411206900_ljag436-B10","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/bjd\/ljac057","article-title":"Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3","volume":"188","author":"Reich","year":"2023","journal-title":"Br J Dermatol"},{"key":"2026111300411206900_ljag436-B11","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1007\/s13555-026-01709-x","article-title":"Comparison of the effects and safety of planned limited-time withdrawal versus continuous maintenance of interleukin inhibitors in patients with psoriasis: a systematic review and network meta-analysis","volume":"16","author":"de Sena","year":"2026","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026111300411206900_ljag436-B12","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1007\/s13555-025-01479-y","article-title":"Dupilumab versus lebrikizumab demonstrates greater likelihood of achieving and maintaining improvements in efficacy outcomes using a placebo-adjusted indirect treatment comparison","volume":"15","author":"St\u00e4nder","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026111300411206900_ljag436-B13","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1007\/s13555-025-01627-4","article-title":"A response to \u2018Letter to the Editor Regarding \u201cDupilumab versus lebrikizumab demonstrates greater likelihood of achieving and maintaining improvements in efficacy outcomes using a placebo-adjusted indirect treatment comparison\u201d\u2019","volume":"16","author":"St\u00e4nder","year":"2026","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026111300411206900_ljag436-B14","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1007\/s13555-025-01622-9","article-title":"Letter to the Editor regarding \u2018Dupilumab versus lebrikizumab demonstrates greater likelihood of achieving and maintaining improvements in efficacy outcomes using a placebo adjusted indirect treatment comparison\u2019","volume":"16","author":"Chovatiya","year":"2026","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026111300411206900_ljag436-B15","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1007\/s13555-024-01226-9","article-title":"Patients with moderate-to-severe atopic dermatitis maintain stable response with no or minimal fluctuations with 1\u2005year of lebrikizumab treatment","volume":"14","author":"Silverberg","year":"2024","journal-title":"Dermatol Ther"},{"key":"2026111300411206900_ljag436-B16","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1111\/jdv.19391","article-title":"Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: results from a phase 2b, randomized, controlled trial","volume":"37","author":"Guttman-Yassky","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026111300411206900_ljag436-B17","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/jdv.14880","article-title":"Drug survival and postdrug survival of first-line immunosuppressive treatments for atopic dermatitis: comparison between methotrexate and cyclosporine","volume":"32","author":"Law Ping Man","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026111300411206900_ljag436-B18","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/bjd.18941","article-title":"Drug survival and postdrug survival of systemic treatments in a national French cohort of children with atopic dermatitis","volume":"183","author":"Chambrelan","year":"2020","journal-title":"Br J Dermatol"},{"key":"2026111300411206900_ljag436-B19","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/bjd\/ljad159","article-title":"Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry","volume":"189","author":"Spekhorst","year":"2023","journal-title":"Br J Dermatol"},{"key":"2026111300411206900_ljag436-B20","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/bjd\/ljad011","article-title":"Successful dose reduction of dupilumab in atopic dermatitis","volume":"188","author":"Ardern-Jones","year":"2023","journal-title":"Br J Dermatol"},{"key":"2026111300411206900_ljag436-B21","first-page":"593","article-title":"Efficacy of abrocitinib in the treatment of moderate-to-severe prurigo phenotype atopic dermatitis","volume":"41","author":"Fan","year":"2025","journal-title":"China J Leprosy Skin Dis"},{"key":"2026111300411206900_ljag436-B22","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1007\/s12325-025-03124-8","article-title":"Onset and long-term maintenance of optimal itch response in adult patients with moderate-to-severe atopic dermatitis treated with dupilumab: post hoc analysis from two phase 3 trials","volume":"42","author":"St\u00e4nder","year":"2025","journal-title":"Adv Ther"},{"key":"2026111300411206900_ljag436-B23","doi-asserted-by":"crossref","first-page":"adv44165","DOI":"10.2340\/actadv.v105.44165","article-title":"Successful dose reduction of Janus-kinase inhibitors in well-controlled atopic dermatitis: a prospective, multicentre, real-world study","volume":"105","author":"Schl\u00f6sser","year":"2025","journal-title":"Acta Derm Venereol"},{"key":"2026111300411206900_ljag436-B24","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"2026111300411206900_ljag436-B25","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jamadermatol.2019.3617","article-title":"Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial","volume":"156","author":"Worm","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2026111300411206900_ljag436-B26","doi-asserted-by":"crossref","first-page":"2585244","DOI":"10.1080\/09546634.2025.2585244","article-title":"Maintained improvement of outcomes related to skin clearance, itch, sleep and quality of life with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 200 weeks in a randomized trial","volume":"36","author":"Wollenberg","year":"2025","journal-title":"J Dermatolog Treat"},{"key":"2026111300411206900_ljag436-B27","first-page":"240","article-title":"The efficacy, tolerability and safety of a new oral formulation of Sandimmun\u00ae\u2013Sandimmun Neoral\u00ae in severe refractory atopic dermatitis","volume":"11","author":"Atakan","year":"1998","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026111300411206900_ljag436-B28","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1093\/ced\/llaf275","article-title":"Clinical course of atopic dermatitis after dupilumab discontinuation: a multicentre real-world study","volume":"50","author":"Barei","year":"2025","journal-title":"Clin Exp Dermatol"},{"key":"2026111300411206900_ljag436-B29","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/17103568251381792","article-title":"Letter: Optimizing dupilumab dosing in atopic dermatitis: real-world evidence","volume":"37","author":"Barei","year":"2026","journal-title":"Dermatitis"},{"issue":"Suppl.","key":"2026111300411206900_ljag436-B30","doi-asserted-by":"crossref","first-page":"AB206","DOI":"10.1016\/j.jaad.2022.06.857","article-title":"34385 Sustained long-term dupilumab efficacy in adult patients with moderate-to-severe atopic dermatitis transitioning from weekly dosing to every other week: results from an open-label extension trial","volume":"87","author":"Beck","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2026111300411206900_ljag436-B31","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1007\/s13555-022-00805-y","article-title":"Tralokinumab efficacy and safety, with or without topical corticosteroids, in North American adults with moderate-to-severe atopic dermatitis: a subanalysis of phase 3 trials ECZTRA 1, 2, and 3","volume":"12","author":"Blauvelt","year":"2022","journal-title":"Dermatol Ther"},{"key":"2026111300411206900_ljag436-B32","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1001\/jamadermatol.2024.2517","article-title":"Long-term effectiveness and reasons for discontinuation of dupilumab in patients with atopic dermatitis","volume":"160","author":"Boesjes","year":"2024","journal-title":"JAMA Dermatol"},{"key":"2026111300411206900_ljag436-B33","doi-asserted-by":"crossref","first-page":"1585368","DOI":"10.3389\/fmed.2025.1585368","article-title":"Recurrence and influencing factors of moderate-to-severe atopic dermatitis after dupilumab withdrawal: a retrospective cohort analysis","volume":"12","author":"Chen","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"2026111300411206900_ljag436-B34","doi-asserted-by":"crossref","first-page":"2235041","DOI":"10.1080\/09546634.2023.2235041","article-title":"Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: a real-world study","volume":"34","author":"Chiricozzi","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"2026111300411206900_ljag436-B35","first-page":"653","article-title":"A body-weight-independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life","volume":"42","author":"Czech","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"2026111300411206900_ljag436-B36","doi-asserted-by":"crossref","first-page":"e13979","DOI":"10.1111\/dth.13979","article-title":"Drug survival of dupilumab compared to cyclosporin in moderate-to-severe atopic dermatitis patients","volume":"33","author":"Dal Bello","year":"2020","journal-title":"Dermatol Ther"},{"key":"2026111300411206900_ljag436-B37","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/1346-8138.17927","article-title":"Discontinuation reasons and drug survival of dupilumab in real-world adult atopic dermatitis patients in three healthcare facilities in Tokyo and Yokohama (2018\u20132023)","volume":"53","author":"Dekio","year":"2025","journal-title":"J Dermatol"},{"key":"2026111300411206900_ljag436-B38","doi-asserted-by":"crossref","first-page":"2200866","DOI":"10.1080\/09546634.2023.2200866","article-title":"Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial.","volume":"34","author":"Flohr","year":"2023","journal-title":"J Dermatolog Treat"},{"issue":"Suppl.","key":"2026111300411206900_ljag436-B39","doi-asserted-by":"crossref","first-page":"AB151","DOI":"10.1016\/j.jaad.2021.06.619","article-title":"27550 Durability of response to abrocitinib in patients with moderate-to-severe atopic dermatitis (AD) after treatment discontinuation in a phase 2b trial","volume":"85","author":"Gooderham","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2026111300411206900_ljag436-B40","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1007\/s13555-022-00764-4","article-title":"Durability of response to abrocitinib in patients with moderate-to-severe atopic dermatitis after treatment discontinuation in a phase 2b trial","volume":"12","author":"Gooderham","year":"2022","journal-title":"Dermatol Ther"},{"key":"2026111300411206900_ljag436-B41","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/bjd\/ljaf236","article-title":"Efficacy and safety of upadacitinib dose escalation and reduction in adults with moderate-to-severe atopic dermatitis: results of a randomized blinded treat-to-target multicentre phase IIIb\/IV study (Flex Up)","volume":"193","author":"Gooderham","year":"2025","journal-title":"Br J Dermatol"},{"key":"2026111300411206900_ljag436-B42","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1365-2133.1995.tb08633.x","article-title":"Cyclosporin in atopic dermatitis: time to relapse and effect of intermittent therapy","volume":"132","author":"Granlund","year":"1995","journal-title":"Br J Dermatol"},{"key":"2026111300411206900_ljag436-B43","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jaad.2010.04.027","article-title":"Enteric-coated mycophenolate sodium versus cyclosporin a as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial","volume":"64","author":"Haeck","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"2026111300411206900_ljag436-B44","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/ced\/llae013","article-title":"Real-world outcomes of children treated with dupilumab for moderate-to-severe atopic dermatitis: a single-centre retrospective observational UK study","volume":"49","author":"Hosseini-Ashrafi","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"2026111300411206900_ljag436-B45","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/bjd.21628","article-title":"Longer dupilumab dosing intervals in adult patients with atopic dermatitis: experience from a French multicentre retrospective cohort study","volume":"187","author":"Jendoubi","year":"2022","journal-title":"Br J Dermatol"},{"key":"2026111300411206900_ljag436-B46","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/cia2.12212","article-title":"Evaluation of long-term disease control with dupilumab therapy using the Atopic Dermatitis Control Tool in real-world clinical practice","volume":"5","author":"Kunimoto","year":"2022","journal-title":"J Cutan Immunol Allergy"},{"key":"2026111300411206900_ljag436-B47","doi-asserted-by":"crossref","first-page":"311","DOI":"10.47102\/annals-acadmedsg.V33N3p311","article-title":"Cyclosporin in the treatment of severe atopic dermatitis: a retrospective study","volume":"33","author":"Lee","year":"2004","journal-title":"Ann Acad Med Singap"},{"key":"2026111300411206900_ljag436-B48","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1097\/CM9.0000000000003159","article-title":"Efficacy and safety of abrocitinib in Chinese patients with moderate-to-severe atopic dermatitis: a post hoc analysis of the JADE REGIMEN phase 3 trial","volume":"137","author":"Li","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"2026111300411206900_ljag436-B49","doi-asserted-by":"crossref","first-page":"101167","DOI":"10.1016\/j.waojou.2025.101167","article-title":"Retrospective analysis of the efficacy and safety of 100\u2005mg abrocitinib in patients with moderate to severe atopic dermatitis: real-world study","volume":"19","author":"Li","year":"2026","journal-title":"World Allergy Organ J"},{"key":"2026111300411206900_ljag436-B50","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/bjd.20883","article-title":"Reasons for discontinuation of dupilumab in adult atopic dermatitis in clinical practice","volume":"186","author":"Marniquet","year":"2022","journal-title":"Br J Dermatol"},{"key":"2026111300411206900_ljag436-B51","doi-asserted-by":"crossref","first-page":"e691","DOI":"10.1111\/jdv.18908","article-title":"Dose reduction of dupilumab in atopic patients with controlled atopic dermatitis: a safe and effective practice?","volume":"37","author":"Mastorino","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026111300411206900_ljag436-B52","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1089\/derm.2024.0146","article-title":"Therapeutic modulation of dupilumab in patients with severe atopic dermatitis: clinical effectiveness in real life","volume":"35","author":"Mastorino","year":"2024","journal-title":"Dermatitis"},{"key":"2026111300411206900_ljag436-B53","doi-asserted-by":"crossref","first-page":"adv00731","DOI":"10.2340\/actadv.v102.295","article-title":"Long-term remission of atopic dermatitis after discontinuation of dupilumab","volume":"102","author":"Miyamoto","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"2026111300411206900_ljag436-B54","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1365-2133.1994.tb02936.x","article-title":"Maintenance treatment with cyclosporin in atopic eczema","volume":"130","author":"Munro","year":"1994","journal-title":"Br J Dermatol"},{"key":"2026111300411206900_ljag436-B55","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/jvc2.60","article-title":"Adjusted dose regimens in dupilumab treatment for atopic dermatitis: daily practice experiences","volume":"1","author":"Olydam","year":"2022","journal-title":"JEADV Clin Pract"},{"key":"2026111300411206900_ljag436-B56","doi-asserted-by":"crossref","first-page":"e15933","DOI":"10.1111\/dth.15933","article-title":"Dupilumab dose spacing after initial successful treatment or adverse events in adult patients with atopic dermatitis: a retrospective analysis","volume":"35","author":"Patruno","year":"2022","journal-title":"Dermatol Ther"},{"key":"2026111300411206900_ljag436-B57","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.jaad.2025.12.088","article-title":"Long-term dupilumab efficacy and safety in moderate-to-severe atopic dermatitis: a real-world single-center retrospective study","volume":"94","author":"Qiu","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"2026111300411206900_ljag436-B58","author":"Reich"},{"issue":"Suppl.","key":"2026111300411206900_ljag436-B59","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.1016\/j.jid.2021.08.043","article-title":"041 Efficacy with continuous dosing, down-titration, or treatment withdrawal after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis","volume":"141","author":"Reich","year":"2021","journal-title":"J Invest Dermatol"},{"key":"2026111300411206900_ljag436-B60","doi-asserted-by":"crossref","first-page":"e1426","DOI":"10.1111\/jdv.19348","article-title":"Evaluation of dupilumab dosing regimen in patients with persistently controlled atopic dermatitis","volume":"37","author":"S\u00e1nchez-Garc\u00eda","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026111300411206900_ljag436-B61","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3906\/sag-1711-7","article-title":"Cyclosporine-A for severe childhood atopic dermatitis: clinical experience on efficacy and safety profile","volume":"48","author":"Saricao\u011flu","year":"2018","journal-title":"Turk J Med Sci"},{"key":"2026111300411206900_ljag436-B62","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.anai.2025.12.017","article-title":"Lebrikizumab is efficacious in adults and adolescents with moderate-to-severe atopic dermatitis regardless of atopic comorbidities","volume":"136","author":"Sher","year":"2026","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2026111300411206900_ljag436-B63","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s40257-022-00702-2","article-title":"Tralokinumab plus topical corticosteroids as needed provides progressive and sustained efficacy in adults with moderate-to-severe atopic dermatitis over a 32-week period: an ECZTRA 3 post hoc analysis","volume":"23","author":"Silverberg","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"2026111300411206900_ljag436-B64","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1111\/all.15439","article-title":"Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis","volume":"77","author":"Spekhorst","year":"2022","journal-title":"Allergy"},{"key":"2026111300411206900_ljag436-B65","doi-asserted-by":"crossref","first-page":"s378","DOI":"10.25251\/skin.8.supp.378","article-title":"Factors associated with persistent efficacy of abrocitinib without flare: a multivariable analysis of the JADE-REGIMEN study","volume":"8","author":"Thyssen","year":"2024","journal-title":"Skin (Milwood, N.Y.)"},{"key":"2026111300411206900_ljag436-B66","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1111\/jdv.20095","article-title":"Optimizing maintenance therapy in responders to abrocitinib induction: a post hoc analysis of JADE REGIMEN","volume":"38","author":"Thyssen","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026111300411206900_ljag436-B67","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s40257-025-00923-1","article-title":"Upadacitinib dose reduction regimen in elderly patients with atopic dermatitis, guided by treat-to-target consensus recommendations","volume":"26","author":"Tong","year":"2025","journal-title":"Am J Clin Dermatol"},{"key":"2026111300411206900_ljag436-B68","doi-asserted-by":"crossref","first-page":"4857510","DOI":"10.1155\/dth\/4857510","article-title":"Long-term dupilumab efficacy and safety in pediatric patients: a real-world experience over 2\u2005years","volume":"2025","author":"Traini","year":"2025","journal-title":"Dermatol Ther"},{"key":"2026111300411206900_ljag436-B69","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1111\/jdv.19528","article-title":"Extending dupilumab dosing intervals in atopic dermatitis: a prospective observational study in a South European tertiary hospital","volume":"38","author":"Valente","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026111300411206900_ljag436-B70","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.jaci.2024.10.031","article-title":"Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis","volume":"155","author":"Weidinger","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"2026111300411206900_ljag436-B71","first-page":"702","article-title":"Atopic dermatitis relapse after treatment discontinuation and predictive factors for relapse: JAK1 inhibitors versus dupilumab","volume":"23","author":"Wu","year":"2025","journal-title":"J Dtsch Dermatol Ges"},{"key":"2026111300411206900_ljag436-B72","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1007\/s13555-024-01225-w","article-title":"Stable response and sustained improvement of itch and sleep symptoms in patients with atopic dermatitis treated with lebrikizumab over 52 weeks","volume":"14","author":"Yosipovitch","year":"2024","journal-title":"Dermatol Ther"},{"key":"2026111300411206900_ljag436-B73","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000547142","article-title":"Lebrikizumab improved itch symptoms and reduced itch interference on sleep over 52 weeks in patients with moderate-to-severe atopic dermatitis in two phase 3 trials","volume":"241","author":"Yosipovitch","year":"2025","journal-title":"Dermatology"},{"issue":"Suppl. 48","key":"2026111300411206900_ljag436-B74","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2133.1996.tb00705.x","article-title":"Treatment of severe atopic dermatitis in childhood with cyclosporin","volume":"135","author":"Zaki","year":"1996","journal-title":"Br J Dermatol"},{"key":"2026111300411206900_ljag436-B75","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/bjd\/ljaf347","article-title":"Rademikibart monotherapy for moderate-to-severe atopic dermatitis in a 1-year, randomized phase II trial (SEASIDE CHINA): initial 2-week dosing, followed by 2-week or 4-week dosing","volume":"194","author":"Zhang","year":"2026","journal-title":"Br J Dermatol"},{"issue":"Suppl. 48","key":"2026111300411206900_ljag436-B76","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2133.1996.tb00704.x","article-title":"The long-term safety and efficacy of cyclosporin in severe refractory atopic dermatitis: a comparison of two dosage regimens","volume":"135","author":"Zonneveld","year":"1996","journal-title":"Br J Dermatol"},{"issue":"Suppl_2","key":"2026111300411206900_ljag436-B77","first-page":"668","article-title":"Improvements in itch and sleep disturbance are maintained up to week 48 with nemolizumab plus TCS\/TCI treatment in patients with moderate-to-severe atopic dermatitis: results from two global phase 3 pivotal studies (ARCADIA 1 and ARCADIA 2)","volume":"191","author":"Silverberg","year":"2024","journal-title":"Br J Dermatol"},{"issue":"suppl.","key":"2026111300411206900_ljag436-B78","doi-asserted-by":"crossref","first-page":"AB205","DOI":"10.1016\/j.jaad.2022.06.851","article-title":"33542 Stability of response prior to baricitinib downtitration or treatment withdrawal: outcome from a substudy of BREEZE AD3","volume":"87","author":"Silverberg","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2026111300411206900_ljag436-B79","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2411834","article-title":"Longer-term safety and efficacy of baricitinib for atopic dermatitis in pediatric patients 2 to &lt;18\u2005years old: a randomized clinical trial of extended treatment to 3.6\u2005years","volume":"35","author":"Wollenberg","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"2026111300411206900_ljag436-B80","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.det.2024.04.005","article-title":"Long-term impact of atopic dermatitis on quality of life","volume":"42","author":"Fitzmaurice","year":"2024","journal-title":"Dermatol Clin"},{"key":"2026111300411206900_ljag436-B81","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3390\/pharmaceutics15020568","article-title":"Targeting interleukin 13 for the treatment of atopic dermatitis","volume":"15","author":"Lytvyn","year":"2023","journal-title":"Pharmaceutics"},{"key":"2026111300411206900_ljag436-B82","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/cia2.12302","article-title":"Immediate exacerbation of atopic dermatitis after switching from upadacitinib to dupilumab: a report of two cases","volume":"6","author":"Ito","year":"2023","journal-title":"J Cutan Immunol Allergy"},{"issue":"Suppl.","key":"2026111300411206900_ljag436-B83","doi-asserted-by":"crossref","first-page":"E88","DOI":"10.1016\/j.jid.2025.10.560","article-title":"Lebrikizumab dosed every 8 weeks as maintenance provides long-lasting response in patients with moderate-to-severe atopic dermatitis","volume":"145","author":"Silverberg","year":"2025","journal-title":"J Invest Dermatol"},{"key":"2026111300411206900_ljag436-B84","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40257-022-00685-0","article-title":"Dupilumab provides acceptable safety and sustained efficacy for up to 4\u2005years in an open-label study of adults with moderate-to-severe atopic dermatitis","volume":"23","author":"Beck","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"2026111300411206900_ljag436-B85","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1007\/s13555-025-01481-4","article-title":"Lebrikizumab rapidly lowers inflammatory biomarkers with clinical correlations in moderate-to-severe atopic dermatitis","volume":"15","author":"Guttman-Yassky","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026111300411206900_ljag436-B86","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jmb.2016.12.005","article-title":"Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13R\u03b11 and IL-13R\u03b12","volume":"429","author":"Popovic","year":"2017","journal-title":"J Mol Biol"},{"key":"2026111300411206900_ljag436-B87","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cea.13491","article-title":"Mechanisms of dupilumab","volume":"50","author":"Harb","year":"2019","journal-title":"Clin Exp Allergy"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljag436\/71575809\/ljag436.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljag436\/71575809\/ljag436.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T05:41:27Z","timestamp":1794548487000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article\/doi\/10.1093\/bjd\/ljag436\/8860168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":87,"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljag436","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"article-number":"ljag436"}}